Results 21 to 30 of about 22,921 (208)

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari, AS Yang, C Festuccia, C Zeller, CA Stidley, CJ Piyathilake, D Ma, D Matei, D Shang, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DW Shen, E Gordian, E San Jose-Eneriz, EA Braga, F Crea, F Fang, H Iwata, H Kantarjian, H Kroeger, HM Kantarjian, J Charlet, J Shia, JA Plumb, JP Issa, JP Issa, JS Kim, K Ghoshal, K Onda, K Ramachandran, K Tikoo, KY Tse, L Ding, L Rothem, MA Kane, ML Orta, NH Nabilsi, R Zhao, RH Finnell, S Fu, S Vijayaraghavalu, SB Baylin, SS Muerkoster, T Tanaka, TB Lee, VF Chekhun, X Chang, XJ Liang, Y Li, Y Oki, Y Zhang, ZG Liu   +55 more
core   +2 more sources

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine

Leukemia Research Reports, 2014
Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was
Daisuke Okamura, Akira Matsuda, Maho Ishikawa, Tomoya Maeda, Ken Tanae, Mika Kohri, Naoki Takahashi, Nobutaka Kawai, Norio Asou, Masami Bessho   +9 more
doaj   +1 more source

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish Registry [PDF]

, 2015
The benefit of azacitidine treatment in survival of high risk myelodysplastic syndromes (MDS) patients compared to conventional care treatment (CCT) has not been established outside clinical trials.
Amigo, M. L., Ardanaz, María Teresa, Bernal del Castillo, Teresa, Luño Fernández, Elisa, Martínez Camblor, Pablo, Nomdedeu, Benet, Paz, Raquel de, Pedro, Carme, Sánchez García, Joaquín, Xicoy, Blanca   +9 more
core   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Genomics mark epigenetic dysregulation as a primary therapeutic target [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective B therapy.
Abate F., Agostinelli C., Amente S., Berti E., Bertolini F., Brundu F., Cerroni L., Dellino G. I., Etebari M., Facchetti F., Falini B., Fuligni F., Indio V., Laginestra M. A., Melle F., Motta G., Orecchioni S., Paulli M., Piccioni R., Pileri A., Pileri S. A., Pimpinelli N., Rabadan R., Rossi M., Sabattini E., Sapienza M. R., Tabanelli V., Talarico G., Tarantino G., Tripodo C., Truni M.   +30 more
core   +2 more sources

Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer [PDF]

, 2016
The high affinity nerve growth factor (NGF) NGF receptor, p75NTR, is a member of the tumor necrosis factor (TNF) receptor superfamily that shares a conserved intracellular death domain capable of inducing apoptosis and suppressing growth in prostate ...
Biordi, Leda, Colapietro, Alessandro, Festuccia, Claudio, Ficorella, Corrado, Gravina, Giovanni Luca, Jitariuc, Ana, Mancini, Andrea, Marampon, Francesco, Sanità, Patrizia, Scarsella, Luca   +9 more
core   +2 more sources

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

Hematology Reports, 2014
Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers, Moshe Bachar, Natasha Savage, Michael Toscano, Paul M. Dainer   +4 more
doaj   +1 more source

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. [PDF]

, 2016
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903),
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott Z, Carter, Corey A, Degesys, Aiste, Kim, Michelle M, Lybeck, Harry, Oronsky, Arnold L, Oronsky, Bryan T, Oronsky, Neil, Reid, Tony, Roswarski, Joseph, Scicinski, Jan J   +12 more
core   +3 more sources

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

BMC Cancer, 2017
Background Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading ...
John F. Seymour, Hartmut Döhner, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Jose Falantes, Richard M. Stone, Mark D. Minden, Jerry Weaver, Steve Songer, C. L. Beach, Hervé Dombret   +20 more
doaj   +1 more source

Development and Validation of a New Storage Procedure to Extend the In-Use Stability of Azacitidine in Pharmaceutical Formulations

Pharmaceuticals, 2021
Stability studies performed by the pharmaceutical industry are principally designed to fulfill licensing requirements. Thus, post-dilution or post-reconstitution stability data are frequently limited to 24 h only for bacteriological reasons, regardless ...
Antonella Iudicello, Filippo Genovese, Valentina Strusi, Massimo Dominici, Barbara Ruozi   +4 more
doaj   +1 more source

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial

eJHaem, 2023
Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux   +10 more
doaj   +1 more source